| General Information | |
|---|---|
| ZINC ID | ZINC000084596919 |
| Molecular Weight (Da) | 466 |
| SMILES | CN(CC(N)=O)Cc1nc(-c2cn(CC3CCS(=O)(=O)CC3)c3c(Cl)cccc23)no1 |
| Molecular Formula | C20Cl1N5O4S1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 115.28 |
| HBA | 6 |
| HBD | 1 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 31 |
| LogP | 1.303 |
| Activity (Ki) in nM | 158.489 |
| Polar Surface Area (PSA) | 132.7 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.64494812 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 14 |
| Fraction csp3 | 0.45 |
| Ilogp | 2.51 |
| Xlogp3 | 1.38 |
| Wlogp | 3.02 |
| Mlogp | 0.85 |
| Silicos-it log p | 1.73 |
| Consensus log p | 1.9 |
| Esol log s | -3.47 |
| Esol solubility (mg/ml) | 0.158 |
| Esol solubility (mol/l) | 0.000338 |
| Esol class | Soluble |
| Ali log s | -3.77 |
| Ali solubility (mg/ml) | 0.0791 |
| Ali solubility (mol/l) | 0.00017 |
| Ali class | Soluble |
| Silicos-it logsw | -5.53 |
| Silicos-it solubility (mg/ml) | 0.00138 |
| Silicos-it solubility (mol/l) | 0.00000295 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -8.16 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 3.7 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -2.313 |
| Logd | 1.462 |
| Logp | -0.277 |
| F (20%) | 0.002 |
| F (30%) | 0.276 |
| Mdck | - |
| Ppb | 81.28% |
| Vdss | 2.166 |
| Fu | 17.19% |
| Cyp1a2-inh | 0.536 |
| Cyp1a2-sub | 0.629 |
| Cyp2c19-inh | 0.67 |
| Cyp2c19-sub | 0.133 |
| Cl | 10.926 |
| T12 | 0.178 |
| H-ht | 0.945 |
| Dili | 0.972 |
| Roa | 0.122 |
| Fdamdd | 0.724 |
| Skinsen | 0.036 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.915 |
| Bcf | 0.388 |
| Igc50 | 2.804 |
| Lc50 | 3.018 |
| Lc50dm | 3.84 |
| Nr-ar | 0.012 |
| Nr-ar-lbd | 0.011 |
| Nr-ahr | 0.01 |
| Nr-aromatase | 0.002 |
| Nr-er | 0.104 |
| Nr-er-lbd | 0.634 |
| Nr-ppar-gamma | 0.104 |
| Sr-are | 0.693 |
| Sr-atad5 | 0.01 |
| Sr-hse | 0.017 |
| Sr-mmp | 0.024 |
| Sr-p53 | 0.438 |
| Vol | 425.66 |
| Dense | 1.093 |
| Flex | 0.292 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.566 |
| Synth | 2.956 |
| Fsp3 | 0.45 |
| Mce-18 | 58.621 |
| Natural product-likeness | -2.14 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |